The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...

Gilead Sciences, a company with a rich portfolio of therapies for life-threatening infectious diseases, has a history of acquisitions that have expanded its focus to pulmonary and cardiovascular ...

(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health insurers to cover preventive care services including those for reducing HIV ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Gilead Sciences stock's long-term outlook depends heavily on how the company fares in each of these categories. Here's a quick SWOT analysis of the big biotech.